Protagonist Therapeutics, Inc. (PTGX) Technical Analysis & Indicators

Protagonist Therapeutics, Inc. (PTGX) — Price $142.84 HealthcareBiotechnology — NASDAQ

Latest reported results:

Technical analysis of Protagonist Therapeutics, Inc. (PTGX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.

Price Performance

1 month-9.22%
3 months+26.56%
Year-to-date+63.54%
1 year+141.20%
3 years+709.29%
5 years+714.83%

52-Week Range

52-week High$160.81
52-week Low$57.90
Avg Volume (90d)634K

Technical Indicators

SMA 50$143.46
SMA 200$108.12
Beta2.11
30-day Volatility (annualised)33.3%
Price vs SMA 50-0.4%
Price vs SMA 200+32.1%

Monthly Close (12 months)

MonthCloseChange
2025-10$78.62
2025-11$90.00+14.5%
2025-12$87.34-3.0%
2026-01$81.80-6.3%
2026-02$92.08+12.6%
2026-03$105.40+14.5%
2026-04$98.97-6.1%
2026-05$99.56+0.6%
2026-06$122.58+23.1%
2026-07$136.64+11.5%
2026-08$147.75+8.1%
2026-09$142.84-3.3%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-09-14$-2.53
2026-09-14$159M
2026-09-14$-0.26$14M
2026-09-14
2026-09-14$0.84$26M
2026-09-14

Price

Price$142.84
Market Cap$9.2B
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book8.71
EV / EBITDA-42.43
Dividend Yield0.00%

Financial Health

Debt / Equity0.02
Current Ratio12.71
Piotroski F-Score3
Altman Z-Score59.63

Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS

Explore sector: Healthcare · Biotechnology

More sections of PTGX: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks